Wexford Capital LP Bluebird Bio, Inc. Transaction History

Wexford Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$16.59 - $33.89 $563,728 - $1.15 Million	-33,980 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$27.5 - $37.92 $934,450 - $1.29 Million	33,980 New	33,980 $1.47 Million
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $327,180 - $415,625	-9,500 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$27.12 - $45.97 $257,640 - $436,715	9,500 New	9,500 $580,000

150

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $643M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Wexford Capital LP, based on Form 13F filings with the SEC.

Stay updated on Wexford Capital LP with notifications on news.